Salud financiera de hoja de balance de Valneva

Salud financiera controles de criterios 3/6

Valneva tiene un patrimonio de los accionistas total de €217.5M y una deuda total de €172.6M, lo que sitúa su ratio deuda-patrimonio en 79.4%. Sus activos y pasivos totales son €516.6M y €299.1M respectivamente.

Información clave

79.4%

Ratio deuda-patrimonio

€172.58m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	€156.34m
Patrimonio	€217.47m
Total pasivo	€299.15m
Activos totales	€516.61m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€303.6M) de AYJ0 superan a sus pasivos a corto plazo (€109.2M).

Pasivo a largo plazo: Los activos a corto plazo de AYJ0 (€303.6M) superan a sus pasivos a largo plazo (€190.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (7.5%) de AYJ0 se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de AYJ0 ha crecido de 19.6% a 79.4% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: AYJ0 tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si AYJ0 tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de Valneva

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva SE to Report Q1, 2025 Results on May 07, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Valneva Se Announces Earnings Guidance for 2024

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Valneva Se Provides Revenue Guidance for the Year 2023

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

Valneva SE announced a financing transaction

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE Provides Financial Guidance of 2023

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Valneva SE Confirms World Health Organization Recommendations for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics License Application for Its Single Shot Chikungunya Vaccine Candidate

Valneva SE Provides Revenue Guidance for the Fiscal Year 2022

Pfizer Inc. and Valneva SE Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine

Valneva SE Announces Supervisory Board Member Appointments

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Valneva Announces Board Appointments

Valneva Successfully Completes Lot-To-Lot Consistency Trial for Its Single-Shot Chikungunya Vaccine Candidate

Valneva Successfully Completes Lot-To-Lot Consistency Trial for Its Single-Shot Chikungunya Vaccine Candidate

EMA Accepts Filing of Marketing Authorization Application for Valneva's Inactivated COVID-19 Vaccine Candidate

Valneva SE Receives Emergency Use Authorization from the United Arab Emirates for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Heterologous Booster Trial of Inactivated, Covid-19 Vaccine Candidate

Valneva SE, Annual General Meeting, Jun 23, 2022

Valneva Provides Regulatory Update on Its Inactivated Covid-19 Vaccine Candidate

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera